Arlington, MA, United States of America

Shobu Odate

USPTO Granted Patents = 5 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Shobu Odate

Introduction

Shobu Odate is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the treatment of genetic disorders. With a total of four patents to his name, Odate's work focuses on innovative methods for addressing alpha-1 antitrypsin deficiency and amyloidosis.

Latest Patents

Odate's latest patents include compositions and methods for treating alpha-1 antitrypsin deficiency. These patents provide methods for introducing double-stranded breaks within the SERPINA1 gene. Additionally, he has developed compositions and methods for reducing and eliminating mutant forms of α1-antitrypsin (AAT), which are particularly relevant for subjects suffering from α1-antitrypsin deficiency (AATD). Another significant area of his research involves compositions and methods for TTR gene editing and treating ATTR amyloidosis. These patents detail methods for editing the TTR gene and provide treatments for subjects with amyloidosis associated with transthyretin (ATTR).

Career Highlights

Shobu Odate is currently employed at Intellia Therapeutics, Inc., where he continues to advance his research in genetic therapies. His work is pivotal in developing innovative solutions for complex medical conditions.

Collaborations

Odate collaborates with esteemed colleagues such as Reynald Michael Lescarbeau and Walter R Strapps. Their combined expertise enhances the potential impact of their research in the field of biotechnology.

Conclusion

Shobu Odate's contributions to biotechnology through his patents and collaborative efforts are paving the way for new treatments for genetic disorders. His innovative approaches are crucial in addressing significant health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…